Table 4.
Main characteristics from the RCT about warfarin included in this review.
| Ref | Year | Ethnic | Population Studied | n | Follow up | Endpoint | Polymorphisms | Homozygotes Action Required | Outcomes (Intervention Group vs. Control Group) |
Availability Test | Dose in Non-Genotype Group |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pirmohamed (EU-PACT) [3] |
2015 | 2% non-European |
AF (72.1%) VT (27.9%) |
455 | 12 weeks | %TTR |
CYP2C9*2,*3 VKORC1 |
VKORC1: 17% CYP2C9*2 and *3: 3.4% |
67.4% vs. 60.3%, p < 0.001 | 2h | Fixed-dose strategy |
| Kimel (COAG) [79] | 2015 | 33% non-European |
AF (23%) DVT or PE (56%) |
1015 | 4 weeks | %TTR |
CYP2C9*2, *3 VKORC1 |
VKORC1: 11% CYP2C9*2 and *3: 1% |
45.2% vs. 45% p = 0.91 |
Not before the 1st dose for 55% of patients | Clinical dosing algorithm |
| Gage (GIFT) [82] |
2017 | 91% European |
Hip or knee arthroplasty |
1650 | 30 and 60 days | Composite (major bleeding, INR ≥ 4, VT, death) |
CYP2C9*2,*3 CYP4F2 |
NA | RR 0.73 (0.56-0.95) p = 0.02 | NA | NA |
AF: atrial fibrillation, DVT: Deep-vein thrombosis, PE: pulmonary embolism. %TTR: percentage time in therapeutic range. NA: Not applicable.